Engineers TV

As a member of Engineers Ireland you have access to Engineers TV, which contains over 700 presentations, technical lectures, courses and seminar recordings as well as events and awards footage and interviews.

Astellas Ireland Co held a ceremony recently to mark the breaking of the ground and start of construction for its new €330m, facility at Kerry Technology Park, Tralee, Co Kerry.

The ceremony, held at the site and Munster Technological University, was attended by enterprise minister Simon Coveney, education minister Norma Foley TD, IDA CEO Michael Lohan, representatives of Kerry County Council, project partners and senior Astellas executives.

Stable supply of high-quality medicines

The new facility, which has been designed with sustainability at its core, will accelerate the expansion of Astellas’ in-house production capabilities and ensure a stable supply of high-quality medicines to patients around the world.

The project is set to create significant employment opportunities in the area, including 600 construction jobs and 100 highly specialised roles in engineering, science, and technology. The facility is planned to be operational by 2028.

Simon Coveney said: “As our Enterprise Policy has a key regional dimension, once again, I wish to celebrate the company’s decision to build its new cutting-edge facility in Tralee which represents a major note of confidence in the southwest region.

"Astellas’ commitment to a facility that will incorporate the highest national and international best practice in energy and environmental design is also aligned with the quality of development that my Department and the IDA are looking to deliver for our citizens, fully in keeping with the Government’s commitment to a decarbonised economy and society.”

Hideki Shima, chief manufacturing officer, Astellas Pharma, said: “Today marks a significant achievement for our company and reflects our continued commitment to expansion and innovation in the region.

"Not only will it further the Astellas vision to be at the forefront of healthcare change by turning innovative science into value for patients, but it will also be a growth opportunity for the many people who will bring this facility to life. Together we hope to build something best in class, producing quality products that people need, and striving to continue putting patients first.”

Louis Collins, executive director, Kerry Operations, Astellas Pharma Ireland Ltd, said: “This is an incredibly exciting day for Astellas, and all those who have helped make this vision a reality. We have been grateful for the time and professionalism of the local authorities and the engagement from the local community throughout this process.

"We also want to thank our project and design partners and the Astellas team across Ireland and globally. I have no doubt that it is this partnership and support that has been key getting us to where we are today, for which we are incredibly grateful.”

CEO of the IDA, Michael Lohan, said: “Astellas’ decision last year to expand its operations in Ireland was warmly welcomed, especially here in Kerry where the company has had an operation since 1990.

Commitment to innovation, sustainability and to the southwest

"Today’s sod-turning is symbolic as it heralds a new chapter for this global pharmaceutical leader in Ireland and is testament to the company’s leadership and commitment to innovation, sustainability and to the southwest region. I wish to congratulate Astellas on today’s ground-breaking and assure the team of IDA Ireland’s continued partnership and support.”

On an environmental level, the building will fall in line with Astellas’ ambitious sustainability values and targets, incorporating the highest national and international best practice in energy and environmental design.

As a result, this project aims to cut water use by approximately half, reduce operational energy intensity by more than one-third, and produce zero waste to landfill (compared with LEED® baseline). These measures along with onsite renewable technology including solar PV panels and biomass boiler underpin Astellas’ efforts in the mitigation of climate change.

Astellas recently announced further investment in Kerry, taking over the lease of the Advanced Technology Building, also at Kerry Technology Park.

Astellas breaks ground on €330 Tralee facility

Established in 1949, and headquartered in Hillerod, north of Copenhagen, Ellab's mission is to reduce time-to-market and mitigate product loss risks for global biotech and pharma companies. This mission is achieved through a comprehensive offering, including onsite validation and calibration management, monitoring systems, consulting, and a continually expanding portfolio of products. 

Since introducing their first thermometers in the 1950s, they have developed an extensive product range, from wireless data loggers to thermocouple systems designed for thermal validation processes and environmental wireless monitoring solutions. 

In recent years, onsite services have gained increasing importance for the company.

Direct presence

Ellab's slogan, 'Global Knowledge with Local Reach', perfectly encapsulates its strategy of establishing a direct presence in key markets through successful mergers and acquisitions (M&As).  

The company began establishing its presence in Ireland in 2020 with the acquisition of Co. Meath based instrumentation products and services supplier, Instrument Technology Ltd, and Cork-based thermal qualification and validation service provider, QualUs.

Its presence was further expanded in 2022 with the acquisitions of Autocal, a Dublin-based validation services provider and CalX, a calibration services provider, based in Co Meath.   

The fact that the owners of the four previous companies – Peter Keane, Gerard Collins, Paul O’Hare, Kevin Davis, Claire McMahon, and Willie McMahon –stayed on in leadership roles helped to both ensure a smooth transition and retain decades of industry experience and knowledge.     

As a trusted global partner to the world's top 20 biotech companies and the world's top 40 pharma companies, Ellab is well positioned in terms of industry-leading expertise and the company’s skilled validation and calibration engineers and technicians are making a significant impact across numerous sites in Ireland.

"2023 was a very busy year for us," remarks Paul O’Hare, managing director of Ellab Ireland. "We saw tremendous growth within the Irish market, and we successfully merged four separate companies into one cohesive unit."

Complete solutions provider

Ellab's standout offering in the Irish market lies in being a complete solutions provider, covering both products and services with an emphasis on managed services where they go beyond just performing required tasks.

For example, in the area of calibrations, Ellab don’t just perform calibrations as required, they also manage the entire process from notifying the client when calibrations are due to ensuring all necessary documentation is uploaded and available online at the touch of a button before their team even leave the site.    

Looking ahead to 2024, Paul O'Hare anticipates even more activity for Ellab Ireland, “we have plans to substantially expand our operations in Ireland over the coming years with a number of significant developments in the pipeline here”.

Amid this growth however, the dedication to maintaining the highest quality standards remains unwavering. Ellab is committed to offering top-tier equipment, employing the best engineers and technicians, and prioritising continuous training and development for its teams, to ensure clients receive the best possible service, both onsite and from support personnel. 

There appears to be exciting developments ahead for Ellab’s Irish operation.

Ellab: Global knowledge with local reach

Solsign uses geospatial technology to identify optimum land for solar installations to generate renewable energy; while ServBlock utilises both space and blockchain technology to track materials for the pharmaceutical industry.  

Three Irish startup companies have secured funding of €50,000 each, as well as technical, business, financial and incubation support through ESA BIC (Business Incubation Centre) Ireland.

ESA BIC Ireland supports Irish companies across the business spectrum that are developing technologies using space assets or resources or solutions that can be used in space.  

L-R: Engin Gem, CTO; Eran Goren, COO; Mattan Lass, CEO.

Numerous sensors and positioning data

Sports Impact Technologies recently joined ESA BIC Ireland and is developing a sports wearable solution that detects head impacts as they happen, in real-time. This innovative sports wearable is worn behind the ear and sends all impact data live to the coach, physio, or parent on the sideline. The technology uses numerous sensors and positioning data from the Galileo constellation of satellites.

Founder of Sports Impact Technologies Eóin Touhy said: “Up to three million sports and recreation related concussions happen each year, and five in 10 concussions go unreported or undetected. Large undetected impacts can lead to second impact syndrome which can be fatal, but studies are now showing that smaller repetitive impacts can affect long-term brain health.

Founder of Sports Impact Technologies Eóin Touhy.

"Sport has a wide range of health benefits, and our mission is to ensure that people can play with peace of mind. The help and support from ESA BIC have allowed us to utilise space technology to develop and grow our solution.”

Solsign, another recent ESA BIC Ireland recruit, uses geospatial analytics to evaluate the suitability of land for solar installations. Solsign’s accurate evaluation can directly connect sellers of vetted land plots with solar developers looking for their next project.

Harnesses power of geospatial data

As the global renewable energy transition gains momentum, sourcing viable land quickly and cost effectively has become challenging. Solsign addresses this problem through an integrated platform that harnesses the power of geospatial data, administrative records and machine learning.

By analysing the solar viability of land plots across parameters like terrain, infrastructure access, legal permissions and more, Solsign identifies and screens the suitability of sites for solar projects.

Founder and CEO of Solsign, Mattan Lass, said: “Our mission is to accelerate and optimise land sourcing for renewable energy projects globally. The partnership with ESA BIC Ireland has allowed us to unlock renewable energy potential in under-served markets like the Balkans, where land data is fragmented. Our scalable, location-agnostic technology provides a comprehensive solution to land scouting obstacles, acting as a catalyst for realising untapped solar capacity.”

Led by a team of legal, geospatial and renewables experts, Solsign is poised to revolutionise how the solar industry discovers land opportunities.

Irish blockchain and pharmaceutical compliance company, ServBlock, is another ESA BIC Ireland company. ServBlock provides a reliable and secure solution for location verification for pharmaceutical companies.

Transparent and verified sourcing of raw materials is a significant and ongoing issue, and the absence of reliable systems to trace the origins of raw materials leaves room for fraud and counterfeit materials. It can also pose significant risks to product quality, patient safety, and regulatory compliance, while also leading to substantial economic losses.

Verification and traceability of raw materials

ServBlock combines robust blockchain technology with state-of-the-art space technologies to offer an unmatched solution for the verification and traceability of raw materials in the pharmaceutical supply chain.

Director of ServBlock John Ward said: “The ESA BIC Ireland funding supports the development and refinement of ServBlock's innovative technology, creating a reliable and secure solution for location verification across various industries. This technology is set to revolutionise the way businesses handle location data, providing enhanced trust and transparency, and mitigating risk.”

Director of ServBlock John Ward.

To date, ESA BIC Ireland has supported 35 companies across Ireland to realise their potential by utilising or developing space technology. Space, a sector growing at an exponential rate, is predicted to be worth $1.3trn globally by 2030.  

ESA BIC Ireland is one of 29 ESA BIC Networks operating across ESA member states.

Irish companies that can demonstrate a connection with space and which are less than five years old can apply to ESA BIC Ireland on a year-round basis. The next application deadline is Friday, October 27. Further information on ESA BIC Ireland can be found at https://www.esaspacesolutions.ie/ 

Space – a frontier close to home for three Irish startups based at Tyndall

NPP, the Dublin based packaging and machinery company, recently unveiled its new brand identity, which showcases the company’s evolution and growth to a complete packaging partner, offering high-performance machinery and systems, materials and engineering services.

The rebrand marks an exciting new chapter for NPP, with the unveiling of a fresh and modern look that truly represents the company's progression and ambitions for its continued growth in 2023 and beyond.

Commitment to innovation, transformation and partnership

The brand expression ‘We complete the package’, is the cornerstone of NPP’s new identity and celebrates the company’s commitment to innovation, transformation and partnership.

With this rebrand, NPP aims to strengthen its position as a leader in the packaging and machinery sector, further progress its product offering and enhance partnerships with customers and suppliers.

With headquarters in Dublin 11, NPP has a rich history dating back to 1984. Since then, the company has grown dramatically, expanding its expertise and product range to offer the widest integrated suite of packaging systems, materials and services available. The company now employs over 80 staff across its operations in Ireland and the UK, with plans to further increase its workforce over the next 12 months.

David Duffy, managing director of NPP said: “We are delighted to unveil the results of many months of extensive work to develop NPP’s new brand identity. Emphasising our commitment to partnership, innovation and growth, our new brand identity communicates the spirit of NPP, while staying true to the heritage of the business.

Food, beverage, agriculture, industrial and pharma

"We believe that it will resonate with our customers, suppliers, and employees and we are excited about what the future holds as we continue to enhance our capabilities and offering to the market."

With nearly 40 years in business, NPP has positioned itself as a complete packaging machinery and materials supply partner for businesses across a wide range of sectors including food, beverage, agriculture, industrial and pharmaceuticals.

"We are confident that our new brand identity will set us apart in the industry and help us build stronger relationships with our customer and supply partners," added director Eoin Mc Donagh.

"We are excited to embark on this new chapter and look forward to continuing to deliver innovative packaging solutions that drive growth and success for our customers."

For more information on NPP and their range of products and services please visit their new website www.npp.ie.

NPP looks to the future with new brand identity

Eoin Lynch writes an analysis of the 'Assessment of alternatives to incineration for vent gas emission abatement to meet sustainability and net zero targets on a pharma manufacturing plant'.

Summary/abstract

Global warming and climate change are commonly cited as being the most severe threat of the 21st century [1]. CO2 emissions have steadily risen by more than 90% since 1970 (EPA). One of the main contributors to the rise in CO2 emissions is industrial processes and fossil fuel combustion, which in total combine for roughly 78% of greenhouse gas emissions over the past half-century.

As such, pharmaceutical companies are increasing their efforts to reduce their carbon footprints in a variety of ways. In this paper, the benefits of moving towards more sustainable vent emission abatement techniques, such as activated adsorption, will be outlined with the aim of increasing awareness of the available measures for carbon footprint reduction for a typical medium to large-sized pharmaceutical company in Ireland.

Introduction

In line with carbon net zero targets by 2050, Irish pharma companies are considering alternative technologies to help reduce their carbon footprint. These companies promote process development and cGMP which extends to CO2 emissions associated with waste treatment, with vent emission abatement being a major contributor to carbon dioxide emissions to the atmosphere.

Carbon dependent technologies such as thermal oxidation via an incinerator is currently one of the most commonly employed vent abatement systems [2], operating under the basic principle of converting volatile organic compounds (VOCs) and other pollutants into CO2 and H2O, utilising excessive temperatures before ultimately exhausting to the atmosphere [3].

A typical waste incinerator treating VOCs produces about 10,000 tonnes CO2/year, an output equivalent to that of 3,500 cars in Ireland on average.

As such, this research examines the potential carbon dioxide emissions reduction that may be achieved with the implementation of alternative technologies for vent emission abatement, given the integration of sustainability is becoming a core value of companies aiming for low carbon manufacturing.

Adsorption overview

Adsorption is a physical process wherein adhesion of gas molecules to the surface of a solid substance occurs [4]. The pharmaceutical industry benefits from the use of a variety of adsorbent materials for VOC removal, including synthetic zeolites and activated carbon, the latter being the more commonly used.

Adsorbent materials typically have high adsorption capacity for VOCs due to their high degree of porosity, large surface area, and versatility for multi-component removal [5]. A typical fixed bed activated carbon adsorber can achieve a removal efficiency of about 97% for common VOCs such as toluene, ethanol, and heptane [6].

The gas stream carrying the VOCs is typically passed through a bed of adsorbent material as part of the VOC adsorption process [7]. The VOCs are adsorbed onto the surface of the adsorbent material as the emission stream passes through the bed. The quantity of VOCs in the gas stream that enters the adsorber, the temperature and humidity of the gas, and the properties of the adsorbent material are all major factors that impact the degree of adsorption [5].

Adsorbers do not produce carbon dioxide emissions while in the adsorption phase, which is a considerable benefit compared to incineration. The adsorbent material withholds the pollutants that have been absorbed, with this material then available to be removed from the adsorber for recycling or suitable disposal.

The reuse of recovered solvent from adsorption also provides an economic benefit as this will reduce the cost associated with raw material purchasing.

Alternatively, these recovered solvents can be sold and reused by a number of waste treatment companies in Ireland that generate solvent blends as raw materials in other processes such as auxiliary fuel production [8].

In addition, the adsorbent material be recycled and reused, which can reduce the environmental impact of such a system by reducing the waste associated with the disposal of activated carbon. By heating the adsorbent material to high temperatures, the captured pollutants can be released, restoring the adsorption capacity of the system for the next cycle.

Adsorber configuration

The three main configurations of adsorption systems used to treat VOC emission streams are fixed-bed, cannister and fluid-bed adsorbers. However, for a medium to large sized pharmaceutical company fixed bed adsorbers provide the most feasible solution [8] to vent emission abatement as outlined below.

Fixed bed adsorbers regenerate adsorbent material by manipulating the environment such that pollutants are desorbed from the surface of the activated carbon. This is an energy-intensive process at large scales but recent developments in the scalability of electrochemical and solvent regeneration may allow for more sustainable regeneration in the future [9].

Design scenario

Consider a medium to large-sized pharma company in Ireland in which an incinerator is the primary waste abatement technique employed on site. Typical large incinerators of this size have an energy demand of about 5.44 MW.

The three contributing factors of the incinerator’s total energy demand are the natural gas supply, liquid waste, and the vent gases which contribute to about 24% of the total incinerator energy demand. The data for this scenario is based on typical energy demands and emissions associated with a pharmaceutical company employing incineration.

Incinerator Carbon Intensity Factor:

In order to determine the potential CO2 emissions reduction by implementing an activated carbon adsorber, the CO2 intensity factor of the incinerator must first be calculated. This was determined using the following equation:

 (1)

With an energy demand of 5.44 MW and assuming continuous operation for the year (8,760 hours), the total energy requirement is as follows:

(2)

The CO2 emissions associated with an incinerator of this size is 9,840 tonnes/year. Therefore:

(3)

CO2 Emissions Reduction with Adsorption Implementation:

Single production area

The average vent gases flow from all production areas was 2750 m3/hr and a calorific value of 34.8 MJ/m3 was assumed given the vents are designed for 5% VOCs, which is assumed to have the same calorific value of natural gas.

A production area produces a toluene-air mixture at 400 m3/hr with a toluene concentration of 5%. By treating these vent gases with a fixed bed activated carbon adsorber, a removal efficiency of 97% can be achieved, thus reducing the incinerator load by 388 m3/hr. The energy demand associated with vent gas abatement was determined as follows:

 (4)

 (5)

The total incinerator energy demand therefore reduces from 5.44 MW to 5.25 MW, which equates to 45.99 x 106 kWh. The total carbon dioxide emissions from the incinerator can then be calculated using the carbon intensity factor as follows:

                 (6)

                /year (7)

The implementation of an activated carbon adsorber vent gas abatement for this production area only can therefore theoretically result in a reduction of 350.19 tonnes of CO2 emissions/year.

Site wide:

As previously mentioned, the average vent gas flow rate was 2,750 m3/hr from all production buildings. A 97% removal efficiency would result in 2,669.44 m3/hr being removed from the vent gas headers and thus reducing the incinerator load. The revised average energy demand associated with vent gas abatement can then be calculated as previous:

  (8)

This results in a 97% reduction in energy demand associated with vent gas abatement, a 1.29 MW reduction in total average energy demand for the entire system to 4.15 MW. This equates to 36.354 x 106 kWh and results in total CO2 emissions as follows:

 (9)

Site-wide implementation of fixed bed adsorbers for vent emission abatement can therefore theoretically reduce carbon dioxide emissions associated with an incinerator by about 2,333 tonnes/year, a percentage reduction of 23.7%. This equates to €70,000/year of savings in carbon credits @ €30/tonne [10].

Conclusions

Fixed-bed activated carbon adsorbers provide a cost-effective solution as an alternative to vent emission abatement technique to incineration.

While the regeneration step has added utility and energy demands compared to other adsorption techniques, their simplistic operation, waste minimisation and low energy intensity in comparison to incineration align with overriding industry efforts to reduce carbon emissions and to continue the effort to shift towards net carbon zero. 

Author: Eoin Lynch, fifth year ME Process & Chemical Engineering, University College Cork; supervisors: Denis Ring, John Linehan, University College Cork.

References

1) Leonzio, G., Fennell, P.S. and Shah, N. (2022). A Comparative Study of Different Sorbents in the Context of Direct Air Capture (DAC): Evaluation of Key Performance Indicators and Comparisons. Applied Sciences, 12(5), p.2618. doi:https://doi.org/10.3390/app12052618.

2) Rucha V.Moharir1PratibhaGautam2SunilKumar1 et al. (2019) Waste treatment processes/technologies for energy recovery, Current Developments in Biotechnology and Bioengineering. Elsevier. Available at: https://www.sciencedirect.com/science/article/pii/B978044464083300004X

3) Kohli, R. (2019). Chapter 16 - Applications of Ionic Liquids in Removal of Surface Contaminants. [online] ScienceDirect. Available at: https://www.sciencedirect.com/science/article/pii/B9780128155776000165

4) Gabelman, A. (n.d.). Adsorption Basics: Part 1. [online] Available at: https://www.aiche.org/sites/default/files/docs/pages/adsorption_basics_part_1.pdf.

5) US EPA, O. (2006). Choosing an Adsorption System for VOC | CICA | US EPA. [online] www3.epa.gov. Available at: https://www3.epa.gov/ttn/catc/cica/other6_e.html

6) Best available techniques (BAT) reference document for waste ... (no date). Available at: https://op.europa.eu/en/publication-detail/-/publication/075477b7-329a-11ea-ba6e-01aa75ed71a1/language-en.

7) Hazardous Waste Management Advances in Chemical and Industrial Waste Treatment and Technologies. (n.d.). Available at: https://bibis.ir/science-books/chemistry/2022/Hazardous%20Waste%20Management%20Advances%20in%20Chemical%20and%20Industrial%20Waste%20Treatment%20and%20Technologies%20by%20Zarook%20Shareefdeen_bibis.ir.pdf [Accessed 27 Mar. 2023].

8) Final Report Economic Study of Solvent Recycling and Treatment. (2010). [online] Available at: https://www.epa.ie/publications/monitoring--assessment/waste/hazardous-waste/Solvents-Economic-Study-Report.pdf

9) Control Techniques for Volatile Organic Compound Emissions from Stationary Sources, EPA 453/R-92-018‌

10) Department of Public Expenditure and Reform (2020) Briefing note: Compliance cost associated with 2020 & 2030 climate ... Available at: https://assets.gov.ie/79025/15ef6330-bfdf-4944-b9ea-a33157681a0e.pdf.

 

Assessment of alternatives to incineration for vent gas emission abatement to meet sustainability and net zero targets on a pharma plant

Biosimulytics, an Irish pharma software firm, has announced that it has signed an exclusive partnership agreement with CGG, a global technology and HPC leader headquartered in Paris, France.

CGG will provide Biosimulytics, which uses artificial intelligence (AI) technologies to dramatically improve drug development, with a fully customised HPC (high performance computing), AI, and cloud solution to rapidly serve the company’s growing volume of pharmaceutical customers worldwide.

Using CGG’s algorithm and HPC expertise enables Biosimulytics to fully scale its breakthrough pharmatech platform which provides pharmaceutical companies with a powerful predictive simulation capability when developing new drug molecules.

Shortens time to market

The Biosimulytics technology shortens the time to market and reduces the risks for important developments in the pharmaceutical industry in getting from molecules to medicine (M2M) and is a key enabling technology for the new era of precision medicine.

CGG’s custom solution meets the specialist needs of Biosimulytics for a high-performing HPC and AI environment that optimises its suite of specialised molecular simulation applications from crystal structure prediction (CSP) to structure-based drug design (SBDD).

Biosimulytics can now run applications at least five times faster than its previous public cloud solution, enabling it to dramatically improve its return on investment and rapidly expand its business.

As a European company offering cloud services hosted in the European Union, CGG also offers the full legal protection of EU regulations for the intellectual property of Biosimulytics and its customers.

Biosimulytics, which is headquartered at NovaUCD in Dublin, is a University College Dublin (UCD) spin-out company from the UCD School of Chemical and Bioprocess Engineering that was founded in 2019. Biosimulytics is also an Enterprise Ireland High-Potential Start-Up (HPSU) company and is strongly backed at the European level through EIT Digital and other EU-funded accelerator programmes.

Biosimulytics is working as a Digital R&D solution provider to some of the world’s leading pharmaceutical companies. The AI drug development market is expected to exceed US$10bn by 2030 growing at a CAGR of 25%.

Peter Doyle, CEO and co-founder of Biosimulytics, said: “We are delighted to announce this exclusive partnership with CGG since our need for a high-performing HPC and AI environment to optimise our Biosim M2M platform is uniquely met with CGG's customised solution.

Much greater probability of success

"The AI drug development space is now at an inflection point and our ambition is to enable the global pharma industry to advance potential molecules to approved medicines quicker and with a much greater probability of success by making AI-powered predictive technology much more accessible and affordable for widespread use by everybody from bg pharma to small emerging biotech companies. Today’s announcement with CGG is a significant milestone on that journey.”

Peter Doyle.

Agnès Boudot, EVP, HPC & Cloud Solutions, CGG, said: “CGG is a global expert in industrial and customised end-to-end HPC and AI services with more than 70 years of experience in pioneering computing solutions.

"After successfully establishing our cloud services offering in the energy, energy transition and mining sectors, where more than 30 external clients are currently directly accessing and using CGG Cloud solution services for delivering insights into their data, we are pleased to expand into the healthcare and life sciences market by supporting Biosimulytics in using AI- and HPC-based technologies to help unlock new and improved therapies faster and more cost efficiently.

"Our experience of hosting and optimising scientific workflows running on over 350 petaflops at an industrial scale ensures that we can provide Biosimulytics with a scalable solution to meet their future growth requirements for this complex HPC and AI workflow.”

Biosimulytics in HPC cloud partnership with CGG to progress market adoption of its AI drug development tech

Theme picker